SNG — Synairgen Share News
0.000.00%
Synairgen presents at ATS 2022
Presentation at ECCMID
Second Price Monitoring Extn
Price Monitoring Extension
Holding(s) in Company
Synairgen to present at ATS 2022
Brief: Synairgen Says A New Clinical Trial Design Needed To Evaluate Efficacy Of SNG001 Against COVID
Synairgen Provides Update on ACTIV-2 Trial
Second Price Monitoring Extn
Price Monitoring Extension
Second Price Monitoring Extn
Price Monitoring Extension
Brief: Synairgen Says Co Was Informed On 8 March That Polar Capital LLP No Longer Has Disclosable Interest In Co
Holding(s) in Company
Holding(s) in Company
Holding(s) in Company
Brief: Synairgen Plc Provides Update On SNG001
Update on SNG001
Holding(s) in Company